Company
BioVaxys Technology Corp.
CNSX:BIOV
Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early-stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
39 stories
BioVaxys Technology closes first tranche of non-brokered private placement for total gross proceeds of $117,500
The company said it intends to use the net proceeds of the private placement for working capital purposes
BioVaxys says initial results from study into universal vaccine against Covid-19 virus family are promising
COO Kenneth Kovan said the interim data supports the development of a safe and well-tolerated solution for sarbecoviruses
BioVaxys Technology signs exclusive distribution deal for cervical lesion treatments from Spain-based Procare Health
The products are Paplicocare, a vaginal gel to prevent and treat HPV-dependent cervical lesions, and Immunocaps, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelializati
BioVaxys Technology files international patent application for its SARS1 vaccine
The action further expands the value of its intellectual property (IP) portfolio, the company said
BioVaxys Technology adds experienced CFO Craig Loverock to its executive team
Loverock brings more than 25 years of accounting and financial management experience in Canada, the US and the UK to the company
BioVaxys Technology announces completed synthesis of its pan-sarbecovirus vaccine candidate and launch of in vivo animal study
BioVaxys president Kenneth Kovan said: "Barring any unforeseen circumstances, we anticipate data from the study in September"
Biovaxys Technology says its French collaborator has excised the first tumors to produce 'dry runs' of its ovarian cancer vaccine
The so-called dry runs an important part of completing the standardized Good Manufacturing Process
BioVaxys says bio-manufacturing partner BioElpida completes next phase of BVX-0918 production for EU Clinical study
"Completion of OVCAR-3 cell banks is another step towards our ability to produce GMP yields of BVX-0918, and brings us closer to our Phase I study in the EU planned for later this year," said BioVaxys president and COO Kenneth Kovan
BioVaxys Technology and Ohio State University reach milestone in joint research evaluating the company's "universal vaccine" for sarbecoviruses
The next step will be immunizing the test animals with BVX-1021, BioVaxys' "booster" vaccine to be administered with current SARS-CoV-2 vaccines, to target sarbecoviruses
BioVaxys confirms first clinical site for Phase I ovarian cancer vaccine trial in France
The study on BVX-0918, the company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer, will take place at Hospices Civils de Lyon in France
BioVaxys files to expand international cervical cancer vaccine patent protection
The biotechnology company said the application would grant BioVaxys' platform broad geographic market coverage outside the US for cervical cancer
BioVaxys enters critical tumor cell supply agreement with Deaconess Research Institute for BVX-0918 bioproduction
The company said the tumor cells will be used for process testing and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process (GMP) production, a requirement for the planned Clinical Trial
BioVaxys Technology to expand cancer vaccine platform with investigator-sponsored trial of colorectal cancer therapy
Colorectal cancer is the third most common malignancy and the second most deadly cancer worldwide, with an estimated 1.9 million new cases diagnosed and 0.9 million deaths globally in 2020
BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus vaccine program with Ohio State University
The biotech has struck a deal with Millipore-Sigma to manufacture BVX-1021, its newly developed vaccine for the strain of coronavirus that causes severe acute respiratory syndrome (SARS1)
BioVaxys says studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, suggest superior cardiac safety
The biotech said a study completed on inhibition of ACE-2 binding activity on its coronavirus vaccine candidate BVX-0320 shows it has superior cardiac safety compared to existing mRNA and Adenovirus Vector vaccines
BioVaxys Technology closes first tranche of C$1M non-brokered private placement
The biotech company issued 2,680,000 units at a price of $0.15 each for gross proceeds of $402,000 in the first tranche
BioVaxys Technology set to raise up to C$1M in a non-brokered private placement
The company said it intends to use the net proceeds of the offering for working capital purposes
BioVaxys announces collaboration with Ohio State University to expand research on reactive pan-sarbecovirus vaccine
The collaboration will leverage BioVaxys' proprietary haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine
BioVaxys tackles cancers and viruses using its robust technology platform
The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous tumor cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhi
Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations to support clinical development
The company’s CoviDTH, is a diagnostic tool for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19
Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations to support clinical development
The company’s CoviDTH, is a diagnostic tool for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19
BioVaxys Technology files international application with Patent Cooperation Treaty for CoviDTH
Although CoviDTH diagnostic results are intended to be visually interpreted, additional patent claims include data capture and analysis via optical, infrared, and ultrasonic images processing methods.
BioVaxys files application with US Patent and Trademark Office for pan-sarbecovirus vaccine
The Vancouver-based biotech company plans on leveraging its invention to immunize people who have either recovered from the coronavirus (COVID-19) infection, or have been fully vaccinated
BioVaxys to present a poster on its coronavirus vaccine candidate BVX-0320 at ISIRV-WHO virtual conference
The company will highlight the SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in a murine model
BioVaxys Technology initiates planned in vivo animal toxicology study of CoviDTH
The Vancouver-based clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics also provided an update regarding a March 2021 agreement with Inotiv Inc, a global contract research org
BioVaxys gears up for study on reduced ACE2 binding capabilities of hapten-modified SARS-CoV-2 proteins
The study will zero in on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BioVaxys’ COVID-19 vaccine candidate BVX-0320
NA Proactive news snapshot: Falcon Gold Corp, Major Precious Metals, Atlas Engineered Products, BioVaxys Technology, New Pacific Metals UPDATE...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
BioVaxys cancer vaccine manufacturing partner Bio Elpida reaches bioproduction milestone
Bio Elpida has completed the technology process transfer with BioVaxys and started the development phase using a ‘quality by design’ approach, which includes establishing the control methods and manufacturing process development
BioVaxys says partner completed synthesis of recombinant SARS-CoV-2 s-protein for its BVX-0320 and CoviDTH programs
BVX-0320 is BioVaxys’ COVID-19 vaccine candidate with CoviDTH its immunodiagnostic product -- and both are headed for clinical trials
BioVaxys Technology says DTH response persists for at least one year after coronavirus exposure or vaccination
Study results showed that the DTH test can be used as a routine diagnostic method to monitor the T cell-mediated response to SARS-CoV-2
BioVaxys says trial affirms CoviDTH approach to screen for T cell mediated immune response to SARS-CoV-2 is effective in humans
Dr Yvelise Barrios, who has led the two clinical studies in Spain’s Hospital Universitario de Canarias, will be a scientific adviser at BioVaxys
BioVaxys receives FDA guidance for it to prepare Investigational New Drug application for clinical trials of CoviDTH
The company now will draft an IND application to support a Phase I/II safety, dosing, and efficacy study of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2
BioVaxys Technology closes first tranche of non-brokered private placement to raise $838,675 in gross proceeds
The aggregate private placement consists of the sale of up to 9,090,909 units for total gross proceeds of about $2 million